Anima Attracts Takeda In Multibillion-Dollar mRNA Translation Modulators Deal For Neurological Diseases

Small-molecule mRNA translation Israeli firm Anima Biotech Inc has landed a new research deal with Takeda Pharmaceutical Co Ltd TAK, covering as many as six programs for genetically-defined neurological diseases.

  • Two-part collaboration could hold as much as $2.3 billion in clinical and commercial milestone payouts.
  • Under the deal, Anima will initially conduct preclinical research for Huntington’s disease and two other small molecule candidates and get $120 million upfront from Takeda.
  • Takeda then has the option to expand the deal from three to six, which will open the door for the remaining $1.2 billion in milestones and tiered royalties.
  • Anima has a licensing deal with another major pharma company, Eli Lilly. According to an agreement in July 2018, Anima worked on several undisclosed protein targets.
  • Lilly paid out $30 million upfront and $14 million in research funding. Anima is eligible for up to $1.05 billion in milestones from this deal.
  • So far in 2021, Takeda has offloaded two of its non-core units - the first portfolio, sold to Hasten Biopharmaceutic for $322 million in January. And last month, Takeda sold four type-2 diabetes products to Teijin Pharma for ¥133 billion.
  • But in addition to these types of deals, Takeda is also plunking down big cash for licensing deals.
  • Last October, Takeda penned a $300 million RNAi alliance with Arrowhead, promising more than $1 billion total. 
  • In January, Takeda put up $100 million with up to $400 million in milestones for KSQ Therapeutics and its CRISPR-screened natural killer cell therapies. And earlier this week, Vivek Ramaswamy’s Genevant — an LNP delivery tech outfit — scored a $600 million deal with Takeda.
  • Recently, Takeda paved the way to boost its immuno-oncology portfolio with the Maverick Therapeutics acquisition.
  • Price Action: TAK shares are trading 0.13% lower at $19.50 in market trading hours on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralNeurological Disorders
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!